Last update 09 Aug 2025

Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Autologous BCMA CAR-T cell(The First Affiliated Hospital of Nanchang University), CG-105-12
Target
BCMA
Action
modulators
Mechanism
BCMA modulators(B-cell maturation protein modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Relapse multiple myeloma
Inactive Indication
Refractory Multiple Myeloma
Originator Organization
The First Affiliated Hospital of Nanchang University
Active Organization
Cells & Genes Biotech (Shanghai) Co.,Ltd
Inactive Organization
The First Affiliated Hospital of Nanchang University
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)
NCT06999031
/ RecruitingEarly Phase 1IIT
An Exploratory Clinical Study on the Safety and Efficacy of Autologous T Cell Injection Targeting BCMA Chimeric Antigen Receptor (CG-105-12) in the Treatment of Patients With Relapsed / Refractory Multiple Myeloma
NCT04194931
/ Unknown statusPhase 1IIT
Study Evaluating the Safety and Efficacy With Sequential Infusion of Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
100 Clinical Results associated with Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Translational Medicine associated with Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Patents (Medical) associated with Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)
Login to view more data
100 Deals associated with Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Multiple MyelomaPhase 1
China
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Relapse multiple myelomaPhase 1
China
The First Affiliated Hospital of Nanchang University
01 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free